Is Prostate Cancer Screening Still Necessary?
The current test for prostate cancer continues to spark debate. In part 1 of WebMD's 2-part series, there's important prostate cancer information that men should have.
To Screen or Not continued...
"The longer your life expectancy, the more important it is to find a prostate cancer early -- so the more important the PSA becomes," says Lepor.
Also important to consider, say experts, is a man's general health. Your life expectancy, says Lepor, should be at least 10 years in order for the PSA screen to be beneficial.
Hall agrees, "The average life expectancy is somewhere around 78 to 80 and most prostate cancer patients live a long time even without treatment. So even if you did find the cancer at that age it's not likely you would do aggressive treatment, so testing is less necessary in men over 70 or 75," he says.
Currently, American Cancer Society (ACS) guidelines recommend doctors offer the PSA blood test and the DRE yearly to men aged 50 with a life expectancy of at least 10 years. Providers should discuss with them the risks, benefits, and limitations of testing. Men at high risk -- including blacks and all men with a close relative who had prostate cancer before age 65 (father, brother, or son) -- should start testing beginning at age 45.
Those men at ultra-high risk -- with several close relatives with prostate cancer at an early age -- are recommended to begin testing at age 40.
At the same time, it's important to note that ACS cautions that no major scientific or medical group recommends routine testing for prostate cancer at this time. Instead, they suggest a case-by-case analysis based on each man's individual history.
Says Lepor: "The bottom line is there are no rules set in stone -- every man needs to talk to his doctor about when to start screening and how often, and in the event a cancer is suspected or diagnosed, they need to openly discuss the options of biopsy and ultimately, treatment," says Lepor.
The Future of Prostate Screening
Two advances that could one day make the PSA obsolete.
In the first advance, Chinnaiyan and his team looked to the body's own immune system for clues about prostate health.
"We are looking at the antibodies or biomarkers produced by the immune system against proteins or protein products made by the cancer cells. We are taking advantage of the body's own immune system activity," says Chinnaiyan.